Welcome to our dedicated page for Know Labs news (Ticker: $KNW), a resource for investors and traders seeking the latest updates and insights on Know Labs stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Know Labs's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Know Labs's position in the market.
Rhea-AI Summary
Know Labs, Inc. (NYSE American: KNW) reported a net loss of $15.29 million dollars in FY2023, compared to a net loss of $20.07 million dollars in FY2022, a reduction in net loss of 23.8%. R&D expenses for FY2023 were $7.73 million dollars, an increase of 43.5% year over year. The company had cash and cash equivalents of $8.02 million dollars, and it expects to raise additional funds through the issuance of equity, preferred stock, and convertible debentures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.33%
Tags
-
Rhea-AI Summary
Know Labs, Inc. (NYSE American: KNW) appoints four new members to its Medical and Scientific Advisory Board. Jeff Hitchcock, Karmeen Kulkarni, Dr. Meng Tan, and Dr. Satish Garg bring extensive clinical diabetes management and FDA expertise to the board. They will support the development and FDA clearance of the company's non-invasive continuous glucose monitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.76%
Tags
-
Rhea-AI Summary
Know Labs, Inc. (NYSE American: KNW) will host a webcast to review business updates and results for its fiscal year ended on September 30, 2023, on December 19, 2023, beginning at 1:30 pm PT. The company is an emerging developer of non-invasive medical diagnostic technology and is progressing in developing the first FDA-cleared non-invasive blood glucose monitoring device.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
Rhea-AI Summary
KNW: Know Labs, Inc. Appoints Three New Directors with Deep Sector Expertise. The company has named John Cronin, Larry Ellingson, and Tim Londergan to its Board of Directors. The new appointees bring extensive sector-relevant experience and deep knowledge of the science and marketplace focused on Know Labs, expanding the board to seven members. John Cronin, the founder and CEO of ipCapital Group, Inc., has played a pivotal role in increasing Know Labs' patent portfolio and global leadership in non-invasive blood glucose monitoring. Larry Ellingson, with 30 years at Eli Lilly, has been instrumental in shaping Know Labs' strategy and global relationships. Tim Londergan, founder and CEO of Tangibly, Inc., brings expertise in trade secret management and enhancing IP portfolios.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Know Labs, Inc. (NYSE American: KNW) will present at the Bernstein CGM Disruptors Conference. The company has seen a 176% increase in patents issued, pending, and in process for non-invasive blood glucose monitoring. They have also published peer-reviewed reports on clinical results and completed production of their Generation 1 working prototype. The CFO will provide updates on the company's diagnostic technology platform and the path to bringing the first FDA-cleared non-invasive blood glucose monitor to the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
-
Rhea-AI Summary
Know Labs, Inc. announces pricing of public offering at $0.25 per share, expected to raise $7 million. Proceeds to be used for product development, clinical studies, and other expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.43%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.5%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
News
Rhea-AI Summary
KNW - Know Labs, Inc. announced results from a new study demonstrating the improved accuracy of its proprietary Bio-RFID sensor technology for non-invasive blood glucose monitoring. The study validated algorithm performance and data preprocessing techniques, achieving an overall Mean Absolute Relative Difference (MARD) of 11.3%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
Know Labs, Inc.
NYSE:KNW
KNW Rankings
KNW Stock Data
57.59M
56.53M
26.81%
2.98%
0.46%
Electromedical and Electrotherapeutic Apparatus Manufacturing
Manufacturing
United States of America
SEATTLE
About KNW
visualant is a public company whose shares trade under the stock symbol, vsul. the visualant spectral pattern matching™ technology directs structured light onto a substance, through a liquid/gas, or off a surface, to capture a unique chromaid™. when matched against existing databases, a chromaid can be used to identify, detect, or diagnosis markers invisible to the human eye. chromaid scanhead modules can be integrated into a variety of mobile or fixed-mount form factors. the patented technology is disruptive, making it possible to effectively conduct analyses in the field that could only previously be performed by large and expensive lab–based tests.